Used in biomedical research to measure bone resorption, the ICTP ELISA kit detects a specific fragment of type I collagen released during bone breakdown. It is widely applied in studies of osteoporosis, rheumatoid arthritis, and bone metastasis to assess collagen degradation and monitor disease progression or treatment response. Researchers use it to evaluate the effectiveness of anti-resorptive drugs, such as bisphosphonates or denosumab, by quantifying changes in ICTP levels in serum or plasma. The assay is also employed in clinical investigations involving liver fibrosis, as elevated ICTP levels can reflect increased extracellular matrix turnover in chronic liver disease. Due to its specificity for cross-linked carboxy-terminal telopeptides, this kit helps distinguish bone-derived collagen breakdown from degradation in other tissues.